Lipoprotein(a) Lowering by Alirocumab and Total CV Events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lipoprotein(a) Lowering by Alirocumab Reduces the Total Burden of Cardiovascular Events Independent of Low-Density Lipoprotein Cholesterol Lowering: ODYSSEY OUTCOMES Trial
Eur Heart J 2020 Oct 14;[EPub Ahead of Print], M Szarek, VA Bittner, P Aylward, M Baccara-Dinet, DL Bhatt, R Diaz, Z Fras, SG Goodman, S Halvorsen, RA Harrington, JW Jukema, PM Moriarty, R Pordy, KK Ray, P Sinnaeve, S Tsimikas, R Vogel, HD White, D Zahger, AM Zeiher, PG Steg, GG SchwartzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.